## **Department of Medicaid**30 Day Change Notice Effective Date: January 1, 2024

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	NO PA REQUIRED PREFERRED
Central Nervous System (CNS) Agents: Anti-	Sumatriptan Nasal Spray
Migraine Agents, Acute	
Central Nervous System (CNS) Agents:	Briviact
Anticonvulsants*	
Central Nervous System (CNS) Agents: Atypical	Abilify Asimtufii
Antipsychotics*	
Central Nervous System (CNS) Agents: Multiple	Kesimpta
Sclerosis*	Teriflunomide
Endocrine Agents: Diabetes – Non-Insulin	Xigduo XR
Infectious Disease Agents: Antibiotics –	Moxifloxacin
Quinolones	
Infectious Disease Agents: Antivirals – HIV*	Apretude
Topical Agents: Antiparasitics	Vanalice

NEW CLINICAL PA REQUIRED PREFERRED DRUGS	
THERAPEUTIC CLASS	CLINICAL CRITERIA REQUIRED PREFERRED
Blood Formation, Coagulation, and Thrombosis	Jivi
Agents: Hemophilia Factor*	
Endocrine Agents: Androgens	Depo-Testosterone
	Testosterone Cypionate
	Testosterone Gel 1.62% Pump
Endocrine Agents: Growth Hormone	Zomacton
Respiratory Agents: Cystic Fibrosis	Trikafta Pak

NEW STEP THERAPY PREFERRED DRUGS	
THERAPEUTIC CLASS STEP THERAPY REQUIRED PREFERRED	
Central Nervous System (CNS) Agents: Atypical Antipsychotics*	Vraylar
Central Nervous System (CNS) Agents: Neuropathic Pain	Ztlido
Endocrine Agents: Diabetes – Insulin	Insulin Degludec
Ophthalmic Agents: Dry Eye Treatments	Xiidra

NEW NON-PREFERRED DRUGS		
THERAPEUTIC CLASS	THERAPEUTIC CLASS PA REQUIRED NON-PREFERRED	
Cardiovascular Agents: Angina, Hypertension and	Inpefa	
Heart Failure		
Cardiovascular Agents: Pulmonary Arterial	Liqrev	
Hypertension*		



#### 30 Day Change Notice Effective Date: January 1, 2024

	T
Central Nervous System (CNS) Agents: Anti-	Zavzpret
Migraine Agents, Acute	
Central Nervous System (CNS) Agents: Atypical	Uzedy
Antipsychotics*	
Central Nervous System (CNS) Agents: Multiple	Aubagio
Sclerosis*	
Endocrine Agents: Androgens	Testosterone Gel 1% Pump
Endocrine Agents: Growth Hormone	Sogroya
<b>Gastrointestinal Agents: Bowel Preparations</b>	Suflave
Immunomodulator Agents: Systemic	Adalimumab-adaz (Generic of Hyrimoz)
Inflammatory Disease	Adalimumab-fkjp (Generic of Hulio)
	Cyltezo
	Hadlima
	Idacio
	Litfulo
	Yuflyma
	Yusimry
Infectious Disease Agents: Antivirals – HIV*	Cimduo
	Symfi
	Symfi Lo
Ophthalmic Agents: Dry Eye Treatments	Miebo
Respiratory Agents: Inhaled Agents	Tiotropium Inhaled Caps

THERAPEUTIC CATEGORIES WITH CHANGES IN CRITERIA	
Cardiovascular Agents: Angina, Hypertension & Heart Failure	
Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents	
Central Nervous System (CNS) Agents: Narcolepsy	
Central Nervous System (CNS) Agents: Neuropathic Pain	
Dermatologic Agents: Oral Acne Products	
Endocrine Agents: Diabetes – Hypoglycemia Treatments	
Endocrine Agents: Diabetes – Non-Insulin	
Endocrine Agents: Endometriosis	
Endocrine Agents: Uterine Fibroids	
Gastrointestinal Agents: Anti-Emetics	
Genitourinary Agents: Benign Prostatic Hyperplasia	
Immunomodulator Agents: Systemic Inflammatory Disease	
Infectious Disease Agents: Antifungals	
Respiratory Agents: Cystic Fibrosis	

REVISED THERAPEUTIC CATEGORY CRITERIA	
THERAPEUTIC CLASS	SUMMARY OF CHANGE



#### 30 Day Change Notice Effective Date: January 1, 2024

Cardiovascular	ADDITIONAL SOTAGLIFLOZIN (INPEFA) CRITERIA:
Agents: Angina,	<ul> <li>Must provide documentation of an inadequate clinical response to at</li> </ul>
Hypertension &	least two SGLT2 Inhibitors (refer to Endocrine Agents: Diabetes –
Heart Failure	Non-Insulin class for complete list)
Central Nervous	STEP THERAPY CRITERIA:
System (CNS)	Must have had an inadequate clinical response of at least 30 days
Agents: Attention	with atomoxetine <b>OR</b> at least two preferred stimulants ADHD
Deficit Hyperactivity	
Disorder Agents	agents.
Disorder Agents	AD Add and Association (Declaration between December
	AR – Adderall Amphetamine/Dextroamphetamine, Dexedrine
	Dextroamphetamine IR, & Zenzedi: a PA is required for patients younger
	than 3 years
	AR – Adderall XR Amphetamine/Dextroamphetamine XR, Atomoxetine,
	Cotempla XR-ODT, Daytrana Methylphenidate Patches, Dexedrine ER
	Dextroamphetamine ER, Dexmethylphenidate, Methylphenidate IR & ER,
	& Xelstrym: a PA is required for patients younger than 6 years
Central Nervous	NON-PREFERRED CRITERIA:
System (CNS)	Must have had an inadequate clinical response of at least 30 days
Agents: Narcolepsy	with at least two preferred drugs - either (1) at least 30 days of
<b>3</b>	modafinil or armodafinil; or (2) at least 7 days of a preferred
	methylphenidate or amphetamine drug
	methylphemidate of amphetamine drug
Central Nervous System	STEP THERAPY CRITERIA:
(CNS) Agents: Neuropathic	
Pain	· · · · · · · · · · · · · · · · · · ·
Pain	with generic Lidocaine patch
Dermatologic Agents: Oral	CLINICAL DA CRITERIA.
Acne Products	Patient must be Prescriber attests that patient is registered and
	meet <mark>s</mark> all of the requirements of the iPLEDGE program
Endocrine Agents:	
_	NON-PREFERRED CRITERIA:
Diabetes – Hypoglycemia	Must have had an inadequate clinical response of at least two one
_	
Diabetes – Hypoglycemia	Must have had an inadequate clinical response of at least two one
Diabetes – Hypoglycemia	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to</li> </ul>
Diabetes – Hypoglycemia	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to</li> </ul>
Diabetes – Hypoglycemia Treatments	Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion  ADDITIONAL INFORMATION
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines,</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines, documented adherence, and appropriate dose escalation (must</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines, documented adherence, and appropriate dose escalation (must achieve maximum recommended dose or document that maximum</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines, documented adherence, and appropriate dose escalation (must achieve maximum recommended dose or document that maximum recommended dose is not tolerated or is clinically inappropriate).</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines, documented adherence, and appropriate dose escalation (must achieve maximum recommended dose or document that maximum recommended dose is not tolerated or is clinically inappropriate).</li> <li>Must include a patient specific document A1C goal if less than</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines, documented adherence, and appropriate dose escalation (must achieve maximum recommended dose or document that maximum recommended dose is not tolerated or is clinically inappropriate).</li> <li>Must include a patient specific document A1C goal if less than 7%</li> </ul> </li> </ul>
Diabetes – Hypoglycemia Treatments  Endocrine Agents:	<ul> <li>Must have had an inadequate clinical response of at least two one preferred drugs OR the inability of the member and/or caregiver to administer a preferred glucagon product in a timely fashion</li> <li>ADDITIONAL INFORMATION         <ul> <li>An inadequate clinical response is defined as the inability to reach A1C goal after at least 120 days of current regimen, with use of multiple two or more drugs concomitantly per ADA guidelines, documented adherence, and appropriate dose escalation (must achieve maximum recommended dose or document that maximum recommended dose is not tolerated or is clinically inappropriate).</li> <li>Must include a patient specific document A1C goal if less than</li> </ul> </li> </ul>



### **Department of Medicaid**30 Day Change Notice Effective Date: January 1, 2024

SUBSEQUENT AUTHORIZATION CRITERIA:   Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring   Must document A1g goal per ADA guidelines and A1g trends including current value (within last 6 months):   Must include a patient specific A1g goal if less than 7%     Must include a patient specific A1g goal if less than 7%     Must include current A1C (within last 6 months):   Must include current A1C (within last 6 months):   Must meet all initial clinical criteria for subsequent authorizations.    Endocrine Agents:   STEP THERAPY CRITERIA:     Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive		
SUBSEQUENT AUTHORIZATION CRITERIA:  • Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring  • Must document A1E goal per ADA guidelines and A1E trends including current value (within last 6 months)  • Must include a patient specific A1C goal if less than 7%  • Must include current A1C (within last 6 months)  • Must meet all initial clinical criteria for subsequent authorizations.  Endocrine Agents:  Endometriosis  STEP THERAPY CRITERIA:  • Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  • Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Gastrointestinal Agents:  Anti-Emetics  • Must have had an inadequate clinical response of at least 90 days with at least one preferred drug  Genitourinary Agents:  Benign Prostatic  Hyperplasia  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Immunomodulator Agents:  Application of the patient's disease to certain diagnoses. Documentation of digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  • Must provide documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as Must provide documentation of Hurley Stage III to be classified as		<ul> <li>Requests may be authorized for patients with a condition that is</li> </ul>
Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring   Must document A1C goal per ADA guidelines and A1C trends including current value (within last 6 months).   Must include a patient specific A1C goal if less than 7%     Must include a patient specific A1C goal if less than 7%     Must include a patient specific A1C goal if less than 7%     Must meet all initial clinical criteria for subsequent authorizations.    Endocrine Agents:		difficult to control (i.e., prone to ketoacidosis, hypoglycemia)
Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring   Must document A1_G goal per ADA guidelines and A1_G trends including current value (within last 6 months).   Must include a patient specific A1_C goal if less than 73/6 Must include a patient specific A1_C goal if less than 73/6 Must include a patient specific A1_C goal if less than 73/6 Must include a patient specific A1_C goal if less than 73/6 Must include a patient specific A1_C goal if less than 73/6 Must meet all initial clinical criteria for subsequent authorizations.    Endocrine Agents:		
treatment and ongoing safety monitoring  Must document A1E goal per ADA guidelines and A1E trends including current value (within last 6 months).  Must include a patient specific A1C goal if less than 7% Must include current A1C (within last 6 months).  Must meet all initial clinical criteria for subsequent authorizations.  Endocrine Agents:  Endometriosis  STEP THERAPY CRITERIA:  Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents:  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Gastrointestinal Agents:  Anti-Emetics  Mon-PREFERED CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Genitourinary Agents:  Benign Prostatic  Hyperplasia  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  FIDALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Must prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		SUBSEQUENT AUTHORIZATION CRITERIA:
o Must document A1€ goal per ADA guidelines and A1€ trends including current value (within last 6 months).  O Must include a patient specific A1€ goal if less than 7% Must include a patient specific A1€ goal if less than 7% Must include current A1€ (within last 6 months).  Endocrine Agents:  Endometriosis  STEP THERAPY CRITERIA:  Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  Endocrine Agents:  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Must have had an inadequate clinical response of at least 90 days with at least one preferred drug  Gastrointestinal Agents:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Fibroids  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and if prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  Immunomodulator Agents:  Systemic Inflammatory Disease  Immunomodulator Agents:  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		<ul> <li>Must provide documentation of patient's clinical response to</li> </ul>
including current value (within last 6 months).  Must include a patient specific A1C goal if less than 7% Must include a patient specific A1C goal if less than 7% Must include current A1C (within last 6 months)  Must meet all initial clinical criteria for subsequent authorizations.  Endocrine Agents:  Endometriosis  STEP THERAPY CRITERIA:  • Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents:  Endocrine Agents:  Endocrine Agents:  • Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  MON-PREFERRED CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic  Hyperplasia  FIADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 90 days of finasteride is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  • Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as		treatment and ongoing safety monitoring
Must include a patient specific A1C goal if less than 7% Must include current A1C (within last 6 months)  • Must meet all initial clinical criteria for subsequent authorizations.  Endocrine Agents: Endometriosis  STEP THERAPY CRITERIA:  • Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  Endocrine Agents: Uterine Fibroids  CLINICAL PA CRITERIA:  • Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  MON-PREFERRED CRITERIA:  • Must have had an inadequate clinical response of at least 90 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  Genitourinary Agents: Whust have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker, and if prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  Immunomodulator Agents: Systemic Inflammatory Disease  ADDITIONAL CROHN'S DISEASE CRITERIA:  • Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as		<ul> <li>Must document A1C goal per ADA guidelines and A1C trends</li> </ul>
Must include current A1C (within last 6 months)  Must meet all initial clinical criteria for subsequent authorizations.  Endocrine Agents: Endometriosis  STEP THERAPY CRITERIA:  Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  CLINICAL PA CRITERIA:  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  MON-PREFERRED CRITERIA:  Must have had an inadequate clinical response of at least 90 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker, and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
Endocrine Agents: Endometriosis  Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  Endocrine Agents: Uterine Fibroids  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Must have had an inadequate clinical response of at least 2 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dl, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  Immunomodulator Agents:  Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  Must provide documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
Endocrine Agents: Endometriosis  • Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  • Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Gastrointestinal Agents: Anti-Emetics  • Must have had an inadequate clinical response of at least 90 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  • Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required.  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  • First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  • Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as		<ul> <li>Must include current A1C (within last 6 months)</li> </ul>
Endometriosis  • Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  • Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Gastrointestinal Agents: Anti-Emetics  • Mon-Preferred Criteria: • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA: • Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  • First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  • Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as		<ul> <li>Must meet all initial clinical criteria for subsequent authorizations.</li> </ul>
Endometriosis  • Must have had an inadequate clinical response of at least 84 days with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  • Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Gastrointestinal Agents: Anti-Emetics  • Mon-Preferred Criteria: • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  • Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA: • Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  • First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  • Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as	Endocrine Agents:	STEP THERAPY CRITERIA:
with at least one preferred NSAID and one preferred oral contraceptive  Endocrine Agents: Uterine Fibroids  CLINICAL PA CRITERIA:  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  NON-PREFERED CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and if prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	_	
Endocrine Agents: Uterine Fibroids  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Mon-Preferred oral contraceptive  NON-Preferred oral contrac		· · · · · · · · · · · · · · · · · · ·
Endocrine Agents: Uterine Fibroids  Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive  Mon-Preferred Criteria:  Mon-Preferred Criteria:  Must have had an inadequate clinical response of at least 43 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 43 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 43 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 43 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90 days of inadequate clinical response of at least 42 days with at least 90		
Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive    Mon-Preferred oral contraceptive		
Must have had an inadequate clinical response of at least 90 days with at least one preferred oral contraceptive    Mon-Preferred oral contraceptive	Endocrine Agents: Uterine	CLINICAL PA CRITERIA:
Gastrointestinal Agents: Anti-Emetics  Mon-Preferred Criteria:  Must have had an inadequate clinical response of at least 3 days with at least one preferred drug  Genitourinary Agents: Benign Prostatic Hyperplasia  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	_	
Gastrointestinal Agents: Anti-Emetics  Must have had an inadequate clinical response of at least 3 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one preferred drug  TADALAFIL (CIALIS) CRITERIA:  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
■ Must have had an inadequate clinical response of at least 3 days with at least one preferred drug    TADALAFIL (CIALIS) CRITERIA:		
Genitourinary Agents: Benign Prostatic Hyperplasia  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	Gastrointestinal Agents:	NON-PREFERRED CRITERIA:
Genitourinary Agents: Benign Prostatic Hyperplasia  Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and if prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	Anti-Emetics	Must have had an inadequate clinical response of at least 7 3 days
Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents:  Systemic Inflammatory  Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		with at least <u>one preferred</u> drug
Must have had an inadequate clinical response of at least 30 days with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents:  Systemic Inflammatory  Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
with at least one alpha-1 adrenergic blocker. and If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents:  Systemic Inflammatory  Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	Genitourinary Agents:	TADALAFIL (CIALIS) CRITERIA:
of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  ALL AUTHORIZATIONS:  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	Benign Prostatic	<ul> <li>Must have had an inadequate clinical response of at least <u>30 days</u></li> </ul>
palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least 90 days of finasteride is required."  Immunomodulator Agents: Systemic Inflammatory Disease  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as	Hyperplasia	
Immunomodulator Agents: Systemic Inflammatory Disease  • First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  • Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as		
Immunomodulator Agents: Systemic Inflammatory Disease  First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
<ul> <li>First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.</li> <li>ADDITIONAL CROHN'S DISEASE CRITERIA:         <ul> <li>Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease</li> </ul> </li> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:         <ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul> </li> </ul>		trial of at least <u>90 days</u> of finasteride <mark>is required</mark> ."
<ul> <li>First line treatment can vary based upon the severity of disease for certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.</li> <li>ADDITIONAL CROHN'S DISEASE CRITERIA:         <ul> <li>Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease</li> </ul> </li> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:         <ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul> </li> </ul>	1	ALL ALITHODITATIONS
Disease  certain diagnoses. Documentation of the patient's disease state and the criteria used to classify the severity is required.  ADDITIONAL CROHN'S DISEASE CRITERIA:  Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
<ul> <li>the criteria used to classify the severity is required.</li> <li>ADDITIONAL CROHN'S DISEASE CRITERIA:         <ul> <li>Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease</li> </ul> </li> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:         <ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul> </li> </ul>	_ ·	
<ul> <li>ADDITIONAL CROHN'S DISEASE CRITERIA:         <ul> <li>Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease</li> </ul> </li> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:         <ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul> </li> </ul>	Disease	
<ul> <li>Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease</li> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:</li> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul>		the criteria used to classify the severity is required.
<ul> <li>Must provide documentation of Crohn's Disease Activity Index (CDAI) score of 220 or higher to be considered moderate to severe disease</li> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:</li> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul>		ADDITIONAL CROUN'S DISEASE CRITERIA.
(CDAI) score of 220 or higher to be considered moderate to severe disease  ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  Must provide documentation of Hurley Stage III to be classified as		
ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:  • Must provide documentation of Hurley Stage III to be classified as		
<ul> <li>ADDITIONAL HIDRADENTIS SUPPURATIVA CRITERIA:</li> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul>		, ,
<ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul>		Severe disease
<ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul>		ADDITIONAL HIDRADENTIS SUPPLIRATIVA CRITERIA
Severe disease		
		Severe discuse
ADDITIONAL PLAQUE PSORIASIS CRITERIA:		ADDITIONAL PLAQUE PSORIASIS CRITERIA:
INDELLIGINE ENGGE LIGHTON CINIFINAL		
		<ul> <li>Must provide documentation of Hurley Stage III to be classified as</li> </ul>
		<ul> <li>To classify as severe disease patient must present at least two of</li> </ul>



# **Department of Medicaid**30 Day Change Notice Effective Date: January 1, 2024

	the following: Psoriasis Area and Severity Index (PASI) score ≥ 11, BSA ≥ 10%, and Static Physician's Global Assessment (sPGA) ≥ 3
Infectious Disease Agents: Antifungals	NON-PREFERRED CRITERIA:  ■ Must have had an inadequate clinical response of at least 7 days with at least one two preferred drugs, if indicated for the diagnosis
Respiratory Agents: Cystic Fibrosis	AR – Trikafta Pak: a PA is required for patients 6 years and older